Advertisement

Spine


  Mesoblast recently completed enrollment for its double-blind, placebo-controlled Phase 2 clinical trial at multiple sites across the United States and Australia to randomize 100 patients with intervertebral disc disease to receive either high doses of the company's allogeneic MPCs…

Zimmer Spine, a division of Zimmer, announced the U.S. market launch of the Optio-C Anterior Cervical System, a next generation, stand-alone cervical device that intends to offer the stability and fusion potential of a traditional ACDF.

Advertisement